
CAS 1215197-37-7
:Fórmula:C18H19F3N4O3
InChI:InChI=1S/C18H19F3N4O3/c19-18(20,21)14-9-25(10-23-14)13(7-11-3-1-2-4-11)16(26)24-15-6-5-12(8-22-15)17(27)28/h5-6,8-11,13H,1-4,7H2,(H,27,28)(H,22,24,26)/t13-/m0/s1
Clave InChI:GKMLFBRLRVQVJO-ZDUSSCGKSA-N
SMILES:C1CCC(C1)C[C@@H](C(=O)NC2=NC=C(C=C2)C(=O)O)N3C=C(N=C3)C(F)(F)F
Filtrar por
Porcentaje de pureza
0
100
|
0
|
50
|
90
|
95
|
100
Se han encontrado 5 productos.
- Precio más bajo
- Precio más alto
- Pureza más baja
- Pureza más alta
- Entrega estimada más rápida
(S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid
CAS:(S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acidFórmula:C18H19F3N4O3Pureza:99%Peso molecular:396.37PF-04991532
CAS:PF-04991532 is a hepatoselective glucokinase activator that reduces plasma glucose and AMP concentrations in the Goto-Kakizaki rat model.Fórmula:C18H19F3N4O3Pureza:99.99%Forma y color:White SolidPeso molecular:396.3637PF 04991532
CAS:PF 04991532 is a cyclopentyl compound that has been shown to have antiviral activity against HIV-1 and hepatitis C virus (HCV) in vitro. It also inhibits the production of inflammatory cytokines such as TNF-α and IL-6, and prevents HCV infection by blocking the interaction of Toll-like receptor 4 with its ligand. PF 04991532 also has an effect on axonal growth in rats with hepatic steatosis. PF 04991532 is administered orally, at a dose of 10 mg/kg once daily for 28 days. This treatment was found to be safe and well tolerated. There were no significant changes in pharmacokinetic parameters between the treatment group and the placebo group. The drug is not metabolized by cytochrome P450 enzymes, but it undergoes glucuronidation after being metabolized by other enzymes, resulting in a glucuronide conjugate (PF04991532-G).Fórmula:C18H19F3N4O3Pureza:Min. 95%Peso molecular:396.36 g/mol





